Euro colorectal cancer therapy market to 2006
The European market for colorectal cancer therapy is forecast to growfrom a value of $277.7 million in 2000 to $564.1 million by 2006, driven by increased use of two groundbreaking treatments, Aventis' Campto (irinotecan) and Sanofi-Synthelabo's Eloxatin (oxaliplatin), according to a new study from Frost & Sullivan.
The boom in sales of Campto, the first alternative to 5-fluorouracil and leucovorin, has assisted Aventis to the position of market leader, ahead of Sanofi-Synthelabo and Wyeth-Lederle, according to the study. It adds that he market will receive a further boost from the arrival of two orally-available 5-FUs, Roche's Xeloda (capecitabine) and Bristol-Myers Squibb's Orzel (UFT and leucovorin calcium).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze